Kairos Pharma, Ltd. KAPA

Kairos Pharma, Ltd. (KAPA) announced that President and CSO Neil Bhowmick will present and moderate at the Discovery on Target Drug Discovery Conference in Boston, Sept. 28–Oct. 1. He will moderate an in-person breakout on Sept. 30, 'Winning the Race against Cancer Therapy Resistance,' outlining Kairos’ strategy to target drug resistance to extend the efficacy of existing cancer therapies. Bhowmick will also deliver an oral plenary, 'Targeting GITR for Immune Action against Tumor Progression,' focusing on KROS-101 for solid tumors and its ability to increase T-cell function and expand effector T-cells, with data from colon tumor models where antibody agonists face limitations. The conference offers on-demand access for virtual attendees. Kairos’ lead candidate ENV-105 targets CD105 to reverse resistance and restore standard therapies; more at kairospharma.com. Moderate visibility boost for Kairos' R&D trajectory with potential partnerships; no near-term clinical or financial milestones.

Kairos Pharma announces strategic collaboration with Bayer to enhance XOFIGO activity in metastatic prostate cancer. Bayer collaboration directly targets XOFIGO enhancement and positions Kairos for major prostate cancer market gains.

Kairos Pharma CEO outlines company initiatives in cancer treatment with potential to transform therapeutic approaches and company trajectory. Potential transformative cancer treatment innovations could fundamentally redefine Kairos Pharma competitive position and prospects.

Kairos Pharma reports breakthrough interim safety data in Phase 1 trial of ENV-105 for EGFR-mutated lung cancer patients, targeting $10 billion drug resistance market. Positive Phase 1 safety data for ENV-105 positions Kairos to capture share in $10 billion lung cancer drug resistance market.

Kairos Pharma, Ltd. (KAPA) announced positive safety results from its Phase 2 trial of ENV-105 in patients with metastatic castration-resistant prostate cancer. The interim analysis showed that ENV-105, a CD105 antagonist, was well tolerated when combined with apalutamide, with no dose-limiting toxicities or unexpected adverse events reported. The trial aims to enroll 100 patients and is currently ongoing at multiple medical centers. Interim efficacy data is expected in September 2025, and the company plans to discuss a potential Phase 3 study with regulatory agencies. Positive safety results from the trial could significantly influence Kairos Pharma's future product development and market positioning.

Kairos Pharma recaps key acquisitions and outlines plans for the balance of 2026 in a letter to shareholders. Acquisitions recap plus 2026 strategic plans represent major moves likely to shift company trajectory and investor views.

Kairos Pharma, Ltd. (KAPA) signed a deal for Celyn Therapeutics’ CL-273, potentially expanding its oncology drug pipeline through licensing or acquisition. Signing a deal for CL-273 adds a new therapeutic candidate to Kairos Pharma's pipeline, marking a significant strategic move with potential to boost market performance.

Kairos Pharma, Ltd. (KAPA) signs deal for Celyn Therapeutics’ CL-273 therapeutic candidate. Deal secures new therapeutic asset, expanding pipeline and positioning for clinical advancement.

Kairos Pharma, Ltd. (KAPA) signed a binding strategic asset acquisition agreement for exclusive worldwide rights to CL-273 from OrbiMed and Torrey Pines Investment-backed Celyn Therapeutics. Binding acquisition of exclusive worldwide rights to CL-273 bolsters Kairos Pharma's pipeline with a strategic asset, poised to significantly influence its competitive position and market performance.

Kairos Pharma, Ltd. (KAPA) signed a term sheet to acquire two clinical oncology assets from Celyn Therapeutics in a strategic move to expand its pipeline. Acquiring two clinical oncology assets marks a major strategic expansion of KAPA's development pipeline with high potential to boost future growth and investor interest.

Kairos Pharma, Ltd. (KAPA) will present at the 3rd Annual DealFlow Discovery Conference, showcasing its latest developments and strategic initiatives to potential investors and industry stakeholders. Participation in the conference may enhance visibility and networking opportunities, potentially influencing future investor sentiment and market positioning.

Kairos Pharma, Ltd. (KAPA) has been awarded the 2025 Clinical Trials Arena Research and Development Excellence Award for its innovative work in advanced prostate cancer treatment. This recognition highlights the company's commitment to advancing cancer research and its potential impact on patient care. Winning a prestigious award in cancer research can significantly enhance the company's reputation and attract investment, influencing its future performance.

Kairos Pharma, Ltd. (KAPA) provided a shareholder update detailing recent developments and future plans. The company highlighted progress in its clinical trials and ongoing efforts to enhance its product pipeline. Additionally, KAPA addressed shareholder concerns and outlined strategies for growth and market expansion. The update reflects the company's commitment to transparency and engagement with its investors. Recent developments in clinical trials and product pipeline may moderately influence financial performance and market positioning.

Kairos Pharma, Ltd. (KAPA) presented findings from its Phase 2 trial of ENV-105 for advanced prostate cancer at the European Society for Medical Oncology (ESMO) meeting. The trial results indicate promising efficacy and safety profiles, suggesting potential for ENV-105 as a treatment option in this patient population. The presentation garnered attention from oncologists and investors alike, highlighting the company's commitment to advancing cancer therapies. The presentation of promising trial results could significantly influence investor sentiment and the company's future trajectory in cancer treatment.

Kairos Pharma, Ltd. (KAPA) announced that it will present positive safety and efficacy data from its Phase 2 prostate cancer trial at the upcoming ESMO 2025 conference. The data is expected to highlight the potential of KAPA's treatment in improving patient outcomes, marking a significant step in the company's clinical development efforts. Positive trial data could significantly enhance KAPA's market position and investor sentiment.

Kairos Pharma, Ltd. (KAPA) announced positive results from its Phase II trial for a prostate cancer treatment, showing promising efficacy and safety profiles. The trial's outcomes are expected to advance the company's development plans and enhance its position in the oncology market. Positive trial results could significantly impact future product development and investor sentiment.

Kairos Pharma, Ltd. (KAPA) announced positive interim results from its Phase 2 trial of ENV105 for advanced prostate cancer, reporting a median progression-free survival of over one year. This promising data suggests potential efficacy for ENV105 in treating this patient population, which could lead to further development and commercialization efforts. Positive interim results from a Phase 2 trial can significantly influence future development and investor sentiment.

Kairos Pharma, Ltd. (KAPA) has announced a virtual Key Opinion Leader (KOL) event to discuss interim efficacy results of ENV105 in advanced prostate cancer. The event aims to provide insights from experts in the field, highlighting the potential impact of ENV105 on treatment options for patients with this condition. The virtual KOL event could significantly influence investor sentiment and the company's strategic positioning in the oncology market.

Kairos Pharma, Ltd. (KAPA) announced the presentation of new Phase 1 data on its ENV105 combination therapy for non-small cell lung cancer at the World Lung Cancer Conference, scheduled for September 6-9, 2025. This data is expected to provide insights into the therapy's efficacy and safety profile, potentially influencing future clinical development and market strategies. The presentation of Phase 1 data could significantly impact the company's future performance and investor sentiment regarding its oncology pipeline.

Kairos Pharma, Ltd. (KAPA) announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, where the company will present its latest developments and strategic initiatives to investors and industry stakeholders. This event is an opportunity for Kairos Pharma to showcase its innovations and engage with potential investors, enhancing its visibility in the market. Participation in a significant investment conference can moderately influence investor sentiment and market positioning.

Kairos Pharma CEO discussed recent Phase 2 safety data, highlighting a significant 165% stock price increase. The company is on track to release efficacy results in September, which could further influence investor sentiment and market performance. The upcoming efficacy results and positive safety data could significantly impact investor sentiment and the company's market trajectory.

Kairos Pharma, Ltd. (NYSE American: KAPA) announced its participation and presentation at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City. CEO John Yu, MD, will host one-on-one meetings during the event, which will also be available virtually on the company's website. Kairos Pharma focuses on innovative cancer therapeutics, with its lead candidate, ENV105, targeting CD105 to overcome drug resistance in cancer treatments. ENV105 is currently in Phase 2 trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer. Participation in a significant investment conference may enhance visibility and investor interest in the company's innovative cancer therapies.

Kairos Pharma, Ltd. (KAPA) presented new data on its small molecule GITR ligand agonist KROS101 at the ASCO 2025 Annual Meeting. The study demonstrated KROS101's ability to enhance T cell function and reduce T reg-mediated suppression, showing superior results compared to the anti-GITR antibody TRX518. CEO John Yu emphasized the potential of KROS101 as a promising cancer immunotherapy, highlighting its dual mechanisms of action. The company is also advancing its lead candidate, ENV105, in clinical trials for various cancers. KROS101's promising data could significantly enhance Kairos Pharma's competitive position in the cancer immunotherapy market.

Kairos Pharma, Ltd. (NYSE American: KAPA) will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York City. CEO John Yu will host one-on-one meetings from 9:00 A.M. to 3:00 P.M. (ET). Interested parties can register by contacting John Perez at [email protected]. Kairos Pharma focuses on oncology therapeutics, with its lead candidate ENV105 targeting CD105 to combat drug resistance in cancer treatments. ENV105 is currently in Phase 2 trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer. D. Boral Capital is an investment bank providing advisory and financing solutions to emerging growth companies globally. Participation in the conference may enhance investor interest and visibility, impacting market sentiment and potential funding opportunities.

Kairos Pharma, Ltd. (KAPA) announced that it will present new data at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting. The presentation is expected to highlight significant advancements in the company's ongoing research and development efforts in oncology, potentially showcasing innovative treatment options and their implications for patient care. The presentation at ASCO could significantly influence investor sentiment and the company's competitive positioning in the oncology market.

Kairos Pharma, Ltd. (KAPA) announced ongoing clinical trials for its lead drug ENV105, targeting prostate and lung cancers. The company received $876,000 from the Department of Defense for a biomarker study and expanded trial sites. Development continues for immune response compounds like KROS101, with promising data presented at major cancer conferences. Despite economic challenges, Kairos remains financially strong due to recent funding and government grants. The company has significant analyst coverage and plans to participate in upcoming healthcare conferences. Ongoing clinical trials and new funding initiatives are likely to significantly impact future performance and investor sentiment.

Kairos Pharma, Ltd. has received a grant from the Department of Defense to support its research on ENV105, a lead compound aimed at preventing drug resistance in lung cancer. This funding will facilitate further studies to enhance the efficacy of ENV105 in combating this prevalent form of cancer, potentially leading to significant advancements in treatment options. The Department of Defense grant signifies a major strategic move that could enhance product development and investor sentiment.

H.C. Wainwright initiated coverage of Kairos Pharma, Ltd. (KAPA) with a Buy rating and a $12 price target, highlighting the company's oncology pipeline that could enhance immune responses against cancer, particularly in metastatic castration-resistant prostate cancer. Other notable analyst calls included upgrades for Block, Zscaler, Ross Stores, TJX, and Fastenal, while Nvidia, Lyft, RxSight, RH, and Best Buy received downgrades. The initiation of coverage with a Buy rating suggests a moderately noticeable influence on KAPA's market performance due to potential investor interest in its oncology pipeline.

Kairos Pharma, Ltd. (KAPA) has completed the safety lead-in of its Phase 2 clinical trial for ENV105, a treatment for metastatic, castration-resistant prostate cancer. The trial combines apalutamide with ENV105 and is currently enrolling patients for the randomized portion. Safety and efficacy data from the safety arm is expected in the first half of 2025. The company is also validating biomarkers to identify patients who may benefit most from the therapy. The trial is supported by a grant from the National Cancer Institute. Completion of the safety lead-in and ongoing enrollment for the randomized trial could significantly impact the company's future performance and investor sentiment.

Kairos Pharma, Ltd. (KAPA) has announced a breakthrough in cancer treatment with its new drug ENV105, which has shown promising results in clinical trials. The CEO highlighted the potential of ENV105 to significantly improve patient outcomes and discussed the company's strategic plans for further development and commercialization. Investors are keenly watching the next steps as the company prepares for regulatory submissions and potential partnerships to enhance market reach. The breakthrough in cancer treatment and upcoming regulatory submissions are likely to significantly impact the company's future and market performance.